Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

86.01
+4.665.73%
Post-market: 86.010.00000.00%19:41 EDT
Volume:1.14M
Turnover:98.44M
Market Cap:5.58B
PE:-6.11
High:87.79
Open:81.01
Low:81.01
Close:81.35
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:1.15
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-535.87
PE(LYR):-183.00

Loading ...

Mirum's rare liver disease drug meets main goal in mid-stage study

Reuters
·
May 04

Mirum Pharmaceuticals Inc : Leerink Partners Raises Target Price to $131 From $118

THOMSON REUTERS
·
May 04

Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat

TIPRANKS
·
May 04

BRIEF-Mirum Pharmaceuticals Announces Primary Endpoint Met In Vistas Study Of Volixibat In Patients With Primary Sclerosing Cholangitis

Reuters
·
May 04

Mirum says volixibat meets primary endpoint in VISTAS Phase 2b PSC trial

Reuters
·
May 04

Mirum Pharmaceuticals Announces Primary Endpoint Met in Vistas Study of Volixibat in Patients With Primary Sclerosing Cholangitis

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Pre-Nda Meeting for Volixibat in Psc Scheduled With FDA Summer 2026; Nda Submission Planned H2 2026

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Volixibat Safety Profile Consistent With Ibat Inhibition; Mainly Gi Events and Elevated Liver Parameters

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Volixibat Shows 2.72 Point Reduction in Pruritus, 1.64 Point Placebo-Adj (P<0.0001)

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Expects Topline Data From Vantage Phase 2B Study of Volixibat in PBC in Q1 2027

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals updates financial calendar, sets quarterly results conference call

Reuters
·
Apr 30

Mirum Pharmaceuticals Inc : Stifel Raises Target Price to $130 From $125

THOMSON REUTERS
·
Apr 29

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 28

Mirum Pharmaceuticals price target raised to $150 from $130 at H.C. Wainwright

TIPRANKS
·
Apr 27

Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $150 From $130

THOMSON REUTERS
·
Apr 27

Mirum Pharmaceuticals Inc : Baird Raises Target Price to $112 From $95

THOMSON REUTERS
·
Apr 27

Mirum announces primary endpoint met in Phase 2b portion of AZURE-1 study

TIPRANKS
·
Apr 27

BUZZ-Mirum Pharma rises as hepatitis delta drug hits main goal

Reuters
·
Apr 27

Mirum says brelovitug meets primary endpoint in Phase 2b AZURE-1 HDV trial

Reuters
·
Apr 27

Mirum Pharmaceuticals Inc - Announces Primary Endpoint Met in Phase 2B Azure-1 Study of Brelovitug

THOMSON REUTERS
·
Apr 27